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Abstract
Background: During the past few years, there has been an increasing interest among the Traditional and Folk
medical practitioners of Sri Lanka in the use of a decoction prepared from Flueggea leucopyrus (Willd.) for treating
various cancers including breast cancer. In the present study, the cytotoxicity of this decoction and its effects on
Heat Shock Protein (HSP) expression and apoptosis were compared in three breast cancer phenotypes, to scientifically
evaluate if a decoction prepared from F. leucopyrus (Willd.) is useful for the treatment of breast cancer.
Methods: Cytotoxic potential of the F. leucopyrus decoction was determined by evaluating its effects in MCF-7,
MDA-MB-231 and SKBR-3 breast cancer cell lines, and MCF-10A (non-cancerous) breast cell line, by use of the
Sulphorhodamine (SRB) assay. The effect of the decoction on HSP gene expression in the above cells was evaluated by
(a) Real time reverse transcription PCR (RT-PCR) and (b) Immunofluorescence analysis of HSP protein expression. Effects
of the decoction on apoptosis were evaluated by (a) fluorescent microscopic examination of apoptosis related
morphological changes and (b) DNA fragmentation (c) Caspase 3/7 assay.
Results: F. leucopyrus decoction can mediate significant cytotoxic effects in all three breast cancer cells phenotypes
(IC50 values: 27.89, 99.43, 121.43 μg/mL at 24 h post incubation periods, for MCF-7, MDA-MB-231, SKBR-3 respectively)
with little effect in the non-cancerous breast cell line MCF-10A (IC50: 570.4 μg/mL). Significant (*P <0.05) inhibitions of
HSP 90 and HSP 70 expression were mediated by the decoction in MCF-7 and MDA-MB-231, with little effect in the
SKBR-3 cells. Clear apoptotic morphological changes on Acridine orange/Ethidium bromide staining and DNA
fragmentation were observed in all three breast cancer cell lines. Caspase 3/7 were significantly (*P <0.05)
activated only in MDA-MB-231 and SKBR-3 cells indicating caspase dependent apoptosis in these cells and
caspase independent apoptosis in MCF-7 cells.
Conclusions: Modulation of HSP 90 and HSP 70 expressions is a possible mechanism by which the decoction of
F. leucopyrus mediates cytotoxic effects MCF-7 and MDA-MB-231 cells. This effect appears to correlate with enhanced
apoptosis in these cells. In SKBR-3 cells, mechanisms other than HSP inhibition may be utilized to a greater extent by
the decoction to mediate the observed cytotoxic effects. Overall findings suggest that the decoction has the potential
to be exploited further for effective treatment of breast cancer.
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Background
During the past few years, much attention has been
focused on exploiting the cytostatic and cytotoxic effects
of phytochemicals to discover novel and effective treat-
ment modalities in different types of human breast cancer
[1]. Results of such investigations have led to the identifi-
cation of a number of phytochemicals with potential to be
beneficial in the management of breast cancer [2–6].
Flueggea leucopyrus (Willd.) also known as, Bushweed, is
a medicinal plant (family: Phyllanthaceae) that grows com-
monly in certain regions of India, Myanmar, Pakistan and
Sri Lanka [7, 8]. The leaves of this plant are traditionally
used to prepare an extract or paste that is utilized as an
alternative to commonly used antibiotics to destroy mag-
gots in sores [7], to treat myiasis and promote wound
healing [8], and for treatment of Otitis media [9]. In Sri
Lanka, many indigenous medical practitioners have been
using a decoction prepared from this plant for the treat-
ment of a variety of cancers despite lack of any data from
scientifically controlled trials to validate such claims.
However, recent research conducted in our laboratory has
provided experimental evidence to confirm that a decoc-
tion prepared from the aerial parts of this plant can exert
a dose dependent cytotoxicity to AN3CA cells (derived
from a hormone and chemotherapy resistant endometrial
cancer), thus providing experimental support for the trad-
itional use of F. leucopyrus for cancer therapy. Apoptosis
and antioxidant activity have been demonstrated to be
possible mechanisms through which such an effect is
mediated [10]. A recent study done by Soysa et al. [11]
has also demonstrated that aqueous extract of F. Leuco-
pyrus leaves can inhibit the proliferation and induce apop-
tosis in Hep2 cells. Breast cancer is one of the most
common female cancers and cause of cancer related
deaths for women in most developed countries [12, 13]. In
Sri Lanka, breast cancer has also become the most preva-
lent form of cancer affecting women [14, 15]. According
to current views, breast cancer can be considered to be a
collection of diseases characterized by malignant cells of
different molecular phenotypes. These tumour subtypes
are primarily recognized by expression of three cellular
receptors, (a) estrogen receptor (ER, HGNC gene symbol
ESR1), (b) progesterone receptor (PR, HGNC gene symbol
PGR) and (c) the epidermal growth factor receptor family
member Her2/Neu (HGNC gene symbol ERBB2). Because
variations in the type of response expected from a particu-
lar therapeutic agent in breast cancer patients may occur
due to variations in the phenotypic subtypes, increased
attention is currently being given to strategies targeted to
breast cancers based upon molecular subtypes [16–20].
However, despite the widespread clinical efficacy of these
treatments, they are ineffective as therapy for receptor
negative disease, and even among those patients that
do initially respond, intrinsic or acquired therapeutic
resistance remains a major obstacle to an effective cure
indicating the need to develop novel therapeutic agents
with increased selectivity and efficacy [21]. Although
apoptosis is generally considered to be the most powerful
defence mechanism against cancer [22], currently, there is
increasing interest worldwide on the role played by Heat
Shock Proteins (HSPs) in cancer development and the
ability of anti-carcinogenic natural compounds and other
anticancer drugs to inhibit their action. HSPs are often
over expressed in many cancers, and HSP 70 and HSP 90
have been reported to be over expressed in different types
of breast cancer cells [23–25]. Their expression often
correlates with increased cell proliferation, lymph node
metastasis, poor response to chemotherapy and poor
survival [26]. HSPs have therefore surfaced as promising
new targets for anti-cancer drug discovery. Therefore, an
evaluation of the effects of the decoction prepared from F.
leucopyrus on expression of HSPs in breast cancer cells
would be very useful for value addition to these traditional
therapies, as well as their further development into glo-
bally acceptable anticancer therapies for breast cancer.
The present investigation was carried out with the main
aims of (a) comparing the cytotoxicity of a F. leucopyrus
decoction to different three breast cancer cell phenotypes,
MCF-7 (ER positive / PR positive, Her2 negative), SKBR-3
(ER negative, PR negative, Her2 positive), and MDA-MB-
231 (Triple negative), and a non-cancerous MCF-10A
breast cell line, and (b) evaluating whether induction of
apoptosis and modulation of HSPs (HSPs 70 and 90) are
possible mechanisms by which the decoction mediates its
anticancer effects in the above cell types.
Method
Chemicals and other reagents
Powdered Dulbecco’s Modified Eagle Medium and TRIzol
reagent were purchased from Invitrogen Life Technologies
(Carlsbad, CA, USA). MCF-7, MDA-MB-231, SKBR-3
and MCF-10A cell lines, Mc Coy’s 5A and L15 medium
were purchased from American Type Culture Collections
(ATCC; Manassas, VA). Sulphorhodamine (SRB), fetal
bovine serum (FBS), streptomycin/penicillin, dimethyl
sulfoxide (DMSO), agarose, and trypsin/EDTA were
purchased from Sigma Aldrich Chemical Company (St.
Louis, MO, USA). M-MLV reverse transcriptase system
was purchased from Promega Cooperation, Madisons,
U.S.A. PCR primers were purchased from Integrated
DNA Technologies (IDT) U.S.A. Primary and secondary
antibodies were purchased from Abcam (Cambridge,
USA).
Preparation of F. leucopyrus decoction
Aerial parts of the plants collected from Wewaldeniya,
Western province, Sri Lanka and identity authenticated
by the Botanist, National Herbarium, Department of
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National Botanic Gardens, Peradeniya, Sri Lanka, (vou-
cher specimen NO: S 03 was deposited in the National
Herbarium, Peradeniya, Sri Lanka) were dried at room
temperature, and ground into powder using an electrical
grinder. A decoction (aqueous extract) was prepared
according to the method recommended traditionally for
administration to cancer patient [10]. Sixty grams (60 g)
of ground plant material was boiled gently with 1.6 L
distilled water for approximately 3 h to reduce the
volume to 200 mL. The extract was then filtered through
a layer of muslin, filtrate centrifuged at 3000 g for
15 min to remove any debris, and the supernatant freeze
dried and stored at −20 °C until required.
Cell culture
The breast cancer cell lines MCF-7 (ER positive/ PR
positive, Her2 negative), MDA-MB-231 (Triple nega-
tive), SKBR-3 (ER negative, PR negative, Her2 positive)
and non-cancerous breast cell line MCF-10A were cul-
tured according to instructions provided by ATCC and
maintained at 37 °C in a 95 % air, 5 % CO2 atmosphere,
and 95 % humidity.
Evaluation of cytotoxicity by Sulphorhodamine (SRB)
Assay
The SRB cytotoxicity assay was performed according to
the method of Samarakoon et al. [27]. Cells (5 × 103/
well) were plated in 96 well culture plates and incubated
for 24 h with the culture medium. At the end of this
period, the medium in each well was removed by aspir-
ation and cells incubated with fresh medium containing
different doses (25, 50, 75, 100, μg/mL) of the decoction.
Treated cells were incubated for a further 24 h. Cells
were then fixed by gentle addition of ice-cold 50 %
trichloroacetic acid solution (50 μL) to the medium in
each well overlaying the cells. The plates were then incu-
bated for 60 min at 4 °C. Wells were rinsed five times
with tap water and then cells were stained with 0.4 %
SRB solution (100 μL stain/well) for 15 min at room
temperature. SRB solution was then poured off and un-
bound dye removed by washing five times with 1 %
acetic acid solution and the plates left to air dry. The
bound SRB dye was then solubilised by adding unbuf-
fered Tris-base solution (200 μL/well), and plates were
placed on a plate shaker for 1 h at room temperature.
Plates were then read at OD 540 nm, using a micro-
plate reader (Synergy HT Micro Plate Reader, BIO-TEK
INSTRUMENTS, USA) and the results expressed as a
percentage cell viability (mean of control group – mean
of treated group/control group × 100 %). All the experi-
ments were carried out in triplicate. Paclitaxel (T 7402-
Sigma) was used as the positive control. Negative
controls received only the medium and DMSO.
Effects of the F. leucopyrus decoction on expression of
Heat Shock Proteins (90 &70): Real time PCR
MCF-7, MDA-MB-231, SKBR-3 breast cancer cells cul-
tured for 24 h were incubated for 24 h with fresh medium
containing different concentrations (10, 20 μg/ mL) of the
decoction (test cells) or 1 % DMSO (control cells). To
evaluate expression of HSP 70 and 90 [28], concentrations
below the IC50value (IC50 indicates 50 % of the cells dead
[29]) of the decoction were selected. Each assay was car-
ried out in three independent experiment in triplicates. At
the end of the incubation period (24 h) cells were har-
vested and used for total RNA extraction for reverse tran-
scription PCR (RT- PCR). Total RNA was isolated from
the cultured cells, using TRIzol reagent according to the
method described by Samarakoon et al. [30]. Total
RNA concentration in the final elutes was determined
by using a spectrophotometer (UV-1700, pharmasprc,
SHIMADZU, Japan). Each sample of isolated RNA was
reverse transcribed by M-MLV reverse transcriptase
system. Real-time PCR reactions were performed in 96-
well plates in Stratagene Mx 3000p real time PCR
machine. Each reaction contained 1 μL of cDNA tem-
plate, 0.5 μL of forward and reverse primers (Primers
for HSP90 F 5″- CGCTCCTGTCTTCTGGCTTC - 3″,
R 5″ - TGGTATCATCAGCAGTAGGGTCA −3″ and
HSP 70 F 5″ - CCATCATCAGCGGACTGTACC −3″,
R 5″- CTGACCCAGACCCTCCCTT −3″ [31]), 2X
MESA GREEN qPCR Master Mix Plus for SYBR Assay
(12.5 μL) bringing the final reaction volume to 25 μL
with PCR water. All reactions were carried out in dupli-
cate for each cDNA sample. As a control for genomic
DNA contamination, an equivalent amount of total
RNA without reverse transcription was tested. A no-
template control (NTC) was also included in each run
for each gene. Finally, a dissociation curve was gener-
ated by increasing temperature starting from 65 to 95 °
C to determine the accuracy and specificity of the reac-
tions. The crossing cycle number (Ct) or the threshold
cycle defined as the PCR cycle at which the fluorescent
signal of the reporter dye crosses an arbitrarily placed
threshold was automatically determined for each reac-
tion by the Mx 3000p software [32]. Expression of HSP
90 and HSP 70 in the decoction treated breast cancer
cells were determined by Real time PCR using a com-
parative threshold cycle method and the fold change in
expression of each gene was normalized to a house
keeping gene (GAPDH gene) [32].
Immunofluorescence analysis and quantification of HSP
90 & HSP 70 expression
Cells (5 × 104) were grown on UV sterilized cell culture
coverslips (Nunc 174950 Thermanox) in a 24 well plate
and maintained for 24 h. Breast cancer cells were then
exposed to different concentrations (10, 20, 40 μg/mL)
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of the decoction (control cells were kept free from the de-
coction) for 24 h. Cells were then rinsed with Phosphate
buffer saline (PBS) twice. To fix the cells, ice cold acetone
(400 μL) was added to each well and kept in 20 °C freezer
for 20 min. Cells were again washed twice with PBS. Fixed
cells were incubated with PBS containing 0.25 % Triton
X-100 (PBST) and 1 % BSA (400 μL) for 30 min at room
temperature to block unspecific binding of the antibodies.
Cells were then incubated with 1:200 primary antibody
(diluted in 1 % BSA in PBST) overnight at 4 °C. Solution
was decanted and cells were washed with PBS five times
(5 min for each time). Cells were then incubated with the
secondary antibody conjugated with fluorescein isothio-
cyanate (FITC) at 1:200 dilutions for 1 h at room
temperature in the dark. Unbound secondary antibody
was decanted and cells washed three times with PBS
(5 min each time). Coverslips were carefully removed
from the wells and placed on glass slides. The cover slips
were dried before mounting with Dako fluorescent
mounting medium (Dako, USA). Samples were analysed
under a fluorescence microscope (Olympus, BX51TRF,
Japan) with 200 × objective at the relevant wavelengths.
Images were recorded digitally using the LSM software
(Zeiss, Germany). With each image capture, care was
taken that the same parameters were used. Non-specific
staining was not observed upon staining with secondary
antibodies only.
Same procedure as described in immunofluorescence
analysis was carried out, except it was carried out in a
96 well plate. To 10 thousand cells in each well 1/5 of
the volume indicated above for each reagent was added.
Quantification was carried out obtaining the fluores-
cence reading via the area scan of each well by the Syn-
ergy HT microplate reader.
Detection of morphological changes related to apoptosis
by fluorescent microscopy
MCF-7, MDA-MB-231 and SKBR-3 cells were grown on
cover slips at a final concentration of 4 × 105 cells/mL in
24 well culture plates for 24 h. The cells were then
exposed to different concentrations of the decoction (10,
20 & 40 μg/mL) (test cells) or 0.1 % DMSO (control
cells) respectively for 24 h. The cells were fixed by 4 %
formaldehyde at room temperature and plated onto glass
slides and subjected to apoptosis analysis by Acridine
orange/Ethidium bromide (AO/EB) staining as described
in Samarakoon et al. [31, 32]. Changes in the nuclei of
cells were observed within 15 minutes after AO/EB
staining under a fluorescence microscope (Olympus,
BX51TRF, and Japan).
DNA fragmentation analysis
DNA fragmentation was used to detect the characteristic
ladder pattern of DNA fragmentation that occurs during
apoptosis, as described by Samarakoon et al. [10] with
slight modifications. Cells (2 × 105 cells/mL) were
exposed to the decoction for 24 h. Trypsinisation was
carried out and the pellets were incubated for 60 min at
50 °C in 100 μl lysis buffer (100 mM Tris–HCl pH 8,
100 mM NaCl and 10 mM EDTA). Proteinase K (10 μl
20 mg/mL stock solution) was then added to the lysis
mixture and further incubated for 30 min at 50 °C.
RNase (3 μL from 10 mg/mL stock solution) was then
added and the mixture incubated for 2 h at 50 °C. DNA
was extracted with phenol chloroform-isoamyl alcohol,
subjected to 2.0 % of agarose gel electrophoresis, stained
with ethidium bromide and visualized under UV light
using a gel-doc system (Quantum- ST4 1100/20 M).
Caspase 3/7 activity
Effect on caspase 3/7 activity was determined in the
three breast cancer cell lines. Cells were treated with the
decoction for 24 h (10, 20, 40 μg/ml). Caspase activity
was assessed using ApoTox-Glo™ triplex assay as per
manufacture’s recommendations (Promega, G6321) and
compared with untreated controls.
Statistical analysis
Statistical analysis was carried out by using Prism 5.0
software (Graphpad Prism, San Diego, CA). The IC50
values were obtained through Non-linear regression ana-
lysis for SRB analysis. Effect of the decoction on HSP
expression were analysed by using one way ANOVA
with Dunnett’s multiple comparison test. Effect of the
decoction on Caspase 3/7 activity were analysed by using
one way ANOVA with Tukey: Compare all pairs of
columns test.
Results and discussion
Effect on relative cell survival
In a previous investigation Samarakoon et al. [10] have
demonstrated that a decoction prepared from the aerial
parts of F. leucopyrus (Willd.) can mediate significant
cytotoxicity to AN3CA cells (estrogen receptor negative
endometrial carcinoma cells) which are sensitive to hor-
mone therapy. In this study we report for the first time
the cytotoxic effects of the decoction on three breast
cancer phenotypes [MCF-7 (ER positive / PR positive,
Her2 negative), SKBR-3 (ER negative, PR negative, Her2
positive), and MDA-MB-231 (Triple negative)]. Results
of the present study demonstrate that F. leucopyrus
decoction can exert significant cytotoxic effects in all
three different phenotypes of breast cancer cells under
test. Results also demonstrate that the decoction can
exert selectively greater cytotoxicity to the breast cancer
cell lines than the non-cancerous breast cells MCF-10A.
Thus as apparent from Fig. 1, that summarizes results of
the SRB assay, on incubation of the cells for 24 h with
Mendis et al. BMC Complementary and Alternative Medicine  (2015) 15:404 Page 4 of 14
the decoction, a dose dependent inhibition of cell sur-
vival was observed with IC50 values of 27.89, 99.43,
121.43, 570.4 μg/mL at 24 post incubation periods, for
MCF-7, MDA-MB-231, SKBR-3 and MCF-10A respect-
ively. IC50 values of the positive control paclitaxel at
24 h were 1.44, 3.47, 4.9, 2.01 μg/mL for MCF-7, MDA-
MB-231, SKBR-3 and MCF-10A respectively. Higher
concentrations of the decoction were used as the decoc-
tion is composed of many compounds and some of them
may interact with the most cytotoxic compound of the
plant. However smaller doses of paclitaxel were used,
since it is a pure compound with IC50 values much
lower than that of the decoction. Paclitaxel is a known
chemotherapy drug used to treat different cancers in-
cluding ovarian, breast and non-small cell lung cancer. It
interferes with normal microtubule growth of the cell by
hyper stabilising its structure [33]. The cytotoxic and
apoptotic effects of paclitaxel have been utilised as a
positive control in a study done by Moongkarndi et al.
[34] in Ovarian and breast cancer cell lines.
Among the three breast cancer cell phenotypes, the
decoction (according to IC50 values obtained in the SRB
assay) appeared to be selectively more cytotoxic to
MCF-7 cells than the other two breast cancer cell types.
Overall results suggest that F. leucopyrus is selectively
more cytotoxic to the Her2 negative cell lines (MCF-7
and MDA-MB-231) than to Her2 positive cell line
SKBR-3. Similar results have been reported for the nat-
ural compound Curcumin [5]. A recent study [35] has
also shown that the highly invasive cell lines such as
MDA-MB-231 were more sensitive to the cytotoxic ef-
fects of the natural compound Magnanol than the less
invasive cells such as MCF-7 and SKBR-3. In contrast,
Genistein (an isoflavone isolated from Soya) has been
reported to exert stronger antiproliferative effects in
Her2 positive breast cancer cell lines than in Her2 nega-
tive MCF-7 cells [36]. Such variations in sensitivity to
the cytotoxic effects may be due to differences in the
rates of absorption of the active compounds into the dif-
ferent breast cancer cell phenotypes as suggested in the
Curcumin study by Altenberg et al. [5] or may be due to
differences in the mechanisms utilized by these com-
pounds to mediate anti-proliferative effects.
Modulation of HSP 90 and HSP 70 expression in Her2
negative phenotypes and Her2 positive phenotype
Heat shock proteins are emerging as important molecules
in cancer development and are considered to be key targets
in cancer therapy. These molecular chaperones are over -
expressed in many human cancers, including breast cancer
[23–25, 36, 37] and enhance cancer cell proliferation, and
protect tumours from therapies such as chemotherapeutic
drugs and surgery, used in cancer management [26]. In
breast cancer cells, over expression of HSP 90 and HSP 70
are reported to correlate with poor prognosis. Recent
investigations have demonstrated that inhibition of breast
cancer cell proliferation by certain plant based compounds
such as Curcumin and the flavanoidal compounds quer-
cetin and taxifolin [23], may in part be mediated via signifi-
cant inhibition of HSP expression in these cells. In this
study, statistically significant inhibition of HSP expression
by the F. leucopyrus decoction was observed in only two of
the breast cancer cell phenotypes (MCF-7, MDA-MB-
231) under investigation, but not in the SKBR-3 phenotype.
This observation was apparent on evaluation of the HSP
mRNA as well as HSP protein expressions in the cells by
use of Real time PCR and immunofluorescence techniques
respectively. Such a difference in HSP expression may be a
reason for the observed differences in cytotoxicity medi-
ated by the decoction in the MCF-7, MDA-MB-231, and
SKBR-3 cells.
On evaluation of HSP 90 gene expression by RT- PCR
(Fig. 2.1) in MCF-7 (Fig. 2.1a) and MDA-MB-231
(Fig. 2.1b) cells treated with either 10 μg/mL or 20 μg/
mL of the decoction, significant (*P <0.05) reduction in
HSP 90 gene expression was observed when compared
to non-treated cells (One way Anova with Dunnett’s
multiple comparison test). In SKBR-3 (Fig. 2.1c) cells no
Fig. 1 Cell survival (by SRB assay) of all three breast cancer cells
(MCF-7, MDA- MB-231 & SKBR-3) and normal breast cell line (MCF-10A).
1.1 Treated with the F. leucopyrus decoction for 24 h. Data values are
expressed as mean ± SD of eight replicates. 1.2 Treated with Paclitaxel
for 24 h (Positive control). Data values are expressed as mean ± SD of
eight replicates
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Fig. 2 Effects of the F. leucopyrus decoction on HSP 90 expression in (a) MCF-7, (b) MDA-MB-231 & (c) SKBR-3 breast cancer cells. 2.1 Real time PCR results of
HSP 90 gene expression. Data are representative of three independent experiments (mean± SD of three replicates). 2.2 Qualitative Immunofluorescence results,
Scale bar: 100 μm. 2.3 Quantitative Immunofluorescence results. Data are representative of five independent experiments (mean± SD of five replicates)
Mendis et al. BMC Complementary and Alternative Medicine  (2015) 15:404 Page 6 of 14
significant effects were observed in comparison to the
controls. These results are supported by the qualitative
(Fig. 2.2) immunofluorescence results. The intracellular
localization of HSP 90 signal in MCF-7 (Fig. 2.2a) or
MDA-MB-231 (Fig. 2.2b) cells were observed to be more
intense in the cytoplasm than in the nucleus. On Visual
observation, the intensity of signal in cell cytoplasm
appeared to decrease with increasing concentration of
the decoction, though the nuclear staining remained
relatively unchanged. Quantitative analysis of immuno-
fluorescence (Fig. 2.3) showed significant (*p <0.05)
reduction in expression of HSP 90 gene of treated MCF-
7 (Fig. 2.3a) or MDA-MB-231 (Fig. 2.3b) cells when
compared to non-treated cells. Qualitative and quantita-
tive immunofluorescence results of HSP 90 in SKBR-3
(Fig. 2.2c and 3c) cells did not show any significant
reduction as the intensity of the signal were maintained
with increasing concentration of the decoction.
Similar results were observed with HSP 70 gene ex-
pression. In the RT- PCR evaluation of HSP 70 (Fig. 3.1)
gene expression in MCF-7 (Fig. 3.1a) or MDA-MB-
231(Fig. 3.1b) cells treated with either 10 μg/mL or
20 μg/mL significant (*P <0.05) reduction in HSP 70
gene expression was observed when compared to non-
treated cells (One way Anova with Dunnett’s multiple
comparison test). In SKBR-3 cells no significant effects
in comparison to controls were observed in the expres-
sion of HSP 70 (Fig. 3.1c), even though a significant dose
dependent cytotoxicity was mediated in these cells by
the decoction, as demonstrated by results of the SRB
assay. Visual observation of HSP 70 immunofluores-
cence (Fig. 3.2) supported the results obtained from the
RT-PCR evaluation. The intracellular localization of HSP
70 signal in MCF-7 (Fig. 3.2a) or MDA-MB-231
(Fig. 3.2b) cells were also observed to be more intense in
the cytoplasm than in the nucleus and the intensity of
the signal in cell cytoplasm appeared to decrease with
increasing concentration of the decoction, though the
nuclear staining remained relatively unchanged. Quanti-
tative analysis of immunofluorescence showed significant
(*p <0.05) reduction in both MCF-7 (Fig. 3.3a) and
MDA-MB-231 (Fig. 3.3b) cell lines. However no signifi-
cant reduction was observed in the qualitative and quan-
titative immunofluorescence results of HSP 70 (Fig. 3.2c
and 3c) in SKBR-3 cells.
In comparison to the quantitative immunofluorescence
results of HSP 90 and HSP 70 expression in the three
breast cancer cell line no significant effects compared to
the controls were observed in in MCF 10a (Fig. 4) nor-
mal breast cell line treated with the different concentra-
tions of decoction.
In contrast to results obtained in the cytotoxicity
study, overall results of the HSP evaluation demonstrates
that HSPs of the highly invasive MDA-MB-231 cells
were more sensitive to the F. leucopyrus decoction than
that of the poorly invasive MCF-7 and SKBR-3 cells.
Thus, on RT-PCR evaluation of HSP mRNA expression,
at a dose of 20 μg/mL of decoction, inhibition of HSP 90
in MDA-MB-231 was significantly greater (about 2.5
fold) than in MCF-7 cells although HSP70 expression
was comparable in the two phenotypes. During the past
decade, HSP 90 has emerged as an exciting target for
cancer therapy because it has been shown to be involved
in maintaining the conformation, stability, activity and cel-
lular localization of several key oncogenic client proteins
such as ERBB2, C-RAF, CDK4, AKT/PKB, steroid hor-
mone receptors, mutant p53, HIF-1α and telomerase
hTERT. It has been demonstrated to be linked to all six
hall marks of cancer described by Hanahan and Weinberg
[38] and modulation of this single drug target is consid-
ered to be effective in simultaneously inhibiting all the
multiple signalling pathways and biological processes that
have been implicated in the development of the malignant
phenotype [38-40]. It is therefore interesting to find from
the overall results of the RT-PCR and immunofluores-
cence evaluations carried out in the present investigation,
that HSP 90 of the highly invasive MDA- MB-231 cells
was more sensitive to the F. leucopyrus decoction than
that in the poorly invasive MCF-7 cells, although effects of
the decoction on HSP 70 expressions were comparable in
the two phenotypes MDA-MB-231 and MCF-7.
Effects of the decoction on apoptosis in the three breast
cancer phenotypes
Apoptosis is a highly regulated process that is well char-
acterized by distinct morphological and physiological
changes in the cell. The morphological changes includes
nuclear condensation, cell shrinkage and membrane
blebbing, whereas the physiological changes are frag-
mentation of nuclear DNA due to activation of specific
endonucleases cleaving nuclear DNA into 80–200 oligo-
nucleosome fragments [41]. These apoptotic changes are
mainly mediated by a group of intracellular proteases
called caspases. There are two caspase activating cas-
cades that regulate apoptosis they are the intrinsic and
extrinsic pathway [42]. Apoptosis is resistant to high ex-
pression of HSP. Thus a decrease in HSP expression
would be expected to result in increased apoptosis in a
cell [43].
Fluorescent microscopic observations of AO/EB stained
(Fig. 5) in MCF-7 (Fig. 5a), MDA- MB-231(Fig. 5b) and
SKBR-3 (Fig. 5c) cells, following the treatment with differ-
ent concentrations of the decoction showed that the
nuclei of viable cells stained uniformly green by acridine
orange, while those of apoptotic cells exhibited yellow to
orange coloration, depending on the degree of loss of
membrane integrity, due to co-staining with ethidium
bromide. In this experiment, yellow staining represented
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Fig. 3 Effects of the F. leucopyrus decoction on HSP 70 expression in (a) MCF-7, (b) MDA-MB-231 & (c) SKBR-3 breast cancer cells. 3.1 Real time PCR results of
HSP gene expression. Data are representative of three independent experiments (mean± SD of three replicates). 3.2 Qualitative Immunofluorescence results,
Scale bar: 100 μm. 3.3 Quantitative Immunofluorescence results. Data are representative of five independent experiments (mean± SD of five replicates)
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early apoptotic cells, while reddish orange staining repre-
sented late apoptotic cells [10]. A dose-dependent increase
in induction of apoptosis was observed in the three breast
cancer cells treated with the different doses of F. leuco-
pyrus decoction for 24 h, as indicated by alterations in cell
staining (described above).
DNA fragmentation was observed in all three breast
cancer cells exposed to the decoction for 24 h. Untreated
control cells showed no evidence of DNA fragmentation
while the smeared laddering pattern was observed in cells
treated with 40 and 100 μg/mL of the decoction for 24 h.
DNA fragmentation was done at higher doses as this
event occurs at the execution phase of apoptosis [44]. All
three breast cancer cell lines treated with positive control
paclitaxel at 5 μg/mL showed DNA fragmentation. MCF
10A was also treated with 100 μg/mL of the decoction
and did not show any laddering pattern (Fig. 6).
To confirm apoptosis quantitatively, caspase 3/7
assay was performed as described in the Methods sec-
tion. As evident from Fig. 7.1, no significant activity
was detected in MCF-7 cells (*P <0.05). However in
MDA-MB-231 cells a statistically significant (*P <0.05)
dose dependent increase in caspase activity was ob-
served at doses <20 μg/ml (Fig. 7.2) and in SKBR-3
cells at doses >20 μg/ml (Fig. 7.3).
Caspase independent pathway (intrinsic pathway or
mitochondrial pathway) is activated in response to death
stimuli such as DNA damage, chemotherapeutic agents,
and UV radiation [41]. Upon activation, results in the
release of cytochrome c (a complex of the mitochondrial
electron transport chain) into the cytosol from the
mitochondria. Cytochrome c function is altered and
binds to a procaspase activating adapter protein known as
apoptotic protease activating factor 1 (Apaf1) forming a
proteasome complex which recruits procaspase 9 along
with dATP that cleaves and activates the precursor to cas-
pase 9. Downstream activation of the procaspases con-
tinues inducing apoptosis [41, 45, 46].
HSP 70 or 90 binds to the Apaf-1, thereby inhibiting
caspases activation and apoptotic cell death. HSP70 has
also been shown to block caspase independent cell death
through its association with apoptosis inducing factor
(AIF) [47]. In this present study there was no significant
increase in expression of Caspase 3/7 mediated in MCF-7
cells by the decoction as caspase 3 is not expressed in
MCF-7 according to publish reports [48]. However the de-
coction significantly inhibited HSP 70 and 90 in MCF −7
cells, hence it can be concluded that in these cells apop-
tosis can occur via a caspase independent pathway.
In the present investigation it was observed that expos-
ure of the decoction to MDA-MB-231 cells significantly
increases Caspase 3/7 expression. Caspase dependent
pathway otherwise known as the extrinsic pathway is
another pathway that occurs in apoptosis [41]. Extrinsic
pathway is triggered when transmembrane receptors such
as fibroblast antigen signalling receptor (FAS), tumor
necrosis factor (TNF), TRAIL and death receptor (DR36)
ligates with complementary ligands such as FasL and
TNFα. On activation, each receptor can form a death
inducing signalling complex (DISC) by recruiting the
adaptor Fas-associated death domain (FADD) and
apical procaspase 8 and 10. Activated caspase 8 and 10
cleaves and activates caspase 3 and 7 resulting in apop-
tosis [41, 45, 46]. Many elements of this pathway are
regulated by the activities of HSP 70 and 90 to help
maintain cellular survival following death receptor
ligation. HSP 70 suppresses apoptosis by binding to and
inhibiting TRAIL and TNF-induced apoptosis [49].
HSP 90 also regulates TNF-mediated cellular survival
which has been linked to their ability to regulate the
stability and activity of a number of components of the
NF-κB activation pathway [49]. HSP 70 and 90 were
inhibited by the decoction and there was an increased
activity of caspase 3/7 suggesting apoptosis in MDA-
MB-231 cells occurs via the extrinsic pathway.
Hsp90 is a homodimer, and comprises three domains.
The N-terminal domain has an ATP-binding site, and nat-
ural products such as geldanamycin and radicicol binds to
this domain. Co-chaperones and client proteins binds to
the highly charged middle domain. ATP usually binds to
the C-terminal nucleotide binding pocket but this domain
has an affinity to cisplatin, novobiocin, epilgallocatechin-
3-gallate (EGCG) and taxol [50]. A study done by Solit et
al. [51] reported that the combination of HSP 90 inhibitor,
17-allylamino-17-demethoxygeldanamycin (geldanamycin
derivative) and taxol can supress AKT activity and subse-
quently sensitize tumor cells to proapoptotic stimuli.
Fig. 4 Effects of the decoction on HSP 70 and HSP 90 expression in
MCF 10a cells treated with F. leucopyrus decoction for 24 h.
Quantitative Immunofluorescence results of HSP 70 and HSP 90
gene expression in MCF 10a cells mediated by the different
concentrations of the decoction, (as analyzed by One way ANOVA
with Dunnett’s post test) Data values are expressed as mean ± S.D
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From the overall results obtained from MCF-7 and
MDA-MB-231, inhibition of HSP’s along with increase
in apoptotic activity may be induced by a single bioactive
compound or through a synergistic effects of different
compounds present in the decoction. Anticancer effect
has been reported in HepG2 cells by synergistic effects
among constituents in an ethanol-water crude extract
of Polyalthia evecta (P. evecta) [52]. However results
contradicting to those obtained from the MCF-7 and
MDA-MB-231 cells was observed in SKBR-3 cell line.
Although Her 2 amplified breast cancer cell lines have
high HSP 90 protein levels, as it constitutively activates
heat-shock factor 1 (HSF1) [53], inhibition of HSP 90
was not statistically significant when compared to the
other breast cancer cell lines. Furthermore caspase 3/7
was activated when treatment with the decoction des-
pite not having any significant inhibitory effect on the
expression of HSP 70 and 90. The reason behind this is
unclear, but a study carried out by Massy 2010 indicates
that VER-155008 (ATP-derivative inhibitor of HSP70)
Fig. 5 Effects of the F. leucopyrus decoction on apoptosis in the three breast cancer cell phenotypes. Fluorescent microscopic observations of
morphological changes in a MCF-7, b MDA-MB-231 or c SKBR-3 cells (magnification 200×), following the treatment with different concentrations of
the decoction, by AO/EB staining
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inhibited the proliferation of human breast cancer cells
but did not enable the apoptotic potential of a small
molecule Hsp90 inhibitor in MDA-MB-468 cells [54].
Natural anticancer compounds have been reported to
mediate their actions via several mechanisms such as
NFkβ inhibition, apoptosis induction, and effects on
microfilament aggregation, antioxidant activity, prote-
asome inhibition and HSP inhibition [55]. However, it is
not clear which of them contributes mainly to the antican-
cer effects mediated by these compounds. It is possible
that in SKBR-3 cells, mechanisms other than HSP
inhibition maybe utilized to a greater extent by the F.
leucopyrus decoction to mediate the observed cytotoxic
effects. Development of effective anti-cancer drugs has
come to a halt as there is lack of phenotype specific anti-
cancer agents [56]. HSP inhibitor such as colchicine,
Fig. 6 DNA fragmentations in MCF-7, MDA-MB-231 or SKBR-3 breast cancer cells treated with F. leucopyrus decoction. Lane 1- 100 bp ladder, Lane
2- MCF-7 Control, Lane 3- MCF-7 Paclitaxel 5 μg/mL, Lane 4-MCF-7 Decoction 40 μg/mL, Lane 5-MCF-7 Decoction 100 μg/mL Lane 6- 100 bp ladder,
Lane 7-MDA-MB-231 Control, Lane 8- MDA-MB-231 Paclitaxel 5 μg/mL, Lane 9- MDA-MB-231 Decoction 40 μg/mL, Lane 10- MDA-MB-231 Decoction
100 μg/mL, Lane 11- 100 bp ladder, Lane 12- SKBR-3 Control, Lane 13- SKBR-3 Paclitaxel 5 μg/mL, Lane 14- SKBR-3 Decoction 40 μg/mL, Lane
15- SKBR-3 Decoction 100 μg/mL, Lane 16- 100 bp ladder, Lane 17- MCF 10A Control, Lane 18- MCF10A Decoction 100 μg/mL
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geldanamycin (GA) are such drugs whose clinical develop-
ment was restricted by their toxicity despite their effect-
iveness at the preclinical stage [51, 56, 57]. Therefore
discovering new compounds that are phenotype specific
and which impose less cytotoxicity to normal cells is cru-
cial for cancer therapy [58]. F. leucopyrus decoction is a
promising new candidate as its cytotoxicity is significant
to breast cancer cell lines and imposes minimalistic effect
on normal breast cell line. Further studies are necessary in
the future to identify the bioactive compounds mediating
the cytotoxic and other related effects in order to deter-
mine whether a single compound or a mixture of com-
pounds in the decoction is responsible for the observed
effects.
Conclusions
F. leucopyrus decoction is significantly cytotoxic to all
three breast cancer cell phenotypes used in this study
(MCF-7, MDA-MB-231 and SKBR-3) with greater
cytotoxicity being exerted in Her2 negative phenotypes
MDA-MB-231 and MCF-7 than in the Her2 positive
phenotype SKBR-3. The decoction also exhibits selective
cytotoxicity to the breast cancer cells in comparison
with the non-cancerous breast cell line MCF-10A. These
results help to rationalize the ethnopharmacological
claims regarding presence of anticancer properties in F.
leucopyrus. Inhibition of heat shock protein expression
(HSP 70 and HSP 90) and enhanced apoptotic activity as
observed in the results of this study appears to be one of
the mechanisms utilized by the decoction to mediate its
cytotoxic effects in the Her2 negative cell lines. In the
Her2 positive SKBR-3 cells, mechanisms other than HSP
inhibition appear to be utilized to a greater extent by the
F. leucopyrus decoction to mediate cytotoxic effects.
Overall findings of the present study suggest that the F.
leucopyrus decoction has the potential to be exploited
further for effective treatment of breast cancer, particu-
larly the Her2 negative phenotypes. Confirmation of the
in vitro results obtained needs to be carried out in the
future by use of appropriate in vivo models.
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